DAY
6-15
6-15
ICU treatment continued; however economic
constraints prompted change
constraints prompted change
Ahmad continued to be monitored through MRI and
laboratory tests. By Day 12, it was anticipated that he
would continue to need mechanical ventilation for some
time, so a tracheostomy was performed. He had
tolerated treatment with Liposomal Amphotericin B
well without side effects for two weeks. His electrolyte
levels and renal function were monitored during this
time, with no noted abnormalities.
laboratory tests. By Day 12, it was anticipated that he
would continue to need mechanical ventilation for some
time, so a tracheostomy was performed. He had
tolerated treatment with Liposomal Amphotericin B
well without side effects for two weeks. His electrolyte
levels and renal function were monitored during this
time, with no noted abnormalities.
The treating physician would have preferred to
continue Liposomal Amphotericin B treatment,
but due to his family's economic constraints,
Ahmad's treatment was changed to conventional
amphotericin B deoxycholate* 50 mg/day
(1 mg/kg) on Day 14. This was continued for a
further four weeks.
continue Liposomal Amphotericin B treatment,
but due to his family's economic constraints,
Ahmad's treatment was changed to conventional
amphotericin B deoxycholate* 50 mg/day
(1 mg/kg) on Day 14. This was continued for a
further four weeks.
*Please refer to the Summary of Product Characteristics of your chosen treatment prior to prescribing.
DAY 16-20
Fever onset
DAY 3-5
Surgical intervention
